The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
IMS 2023 | Immune profiling in patients with multiple myeloma treated with cellular therapies
Bruno Paiva, PhD, University of Navarra, Pamplona, Spain, discusses the importance of immune profiling in patients with multiple myeloma early on in disease evolution, especially in the era of novel cellular therapies. Additionally, Dr Paiva elaborates on the value of using biallelic events in BCMA and GPRC5D as biomarkers for immunotherapy resistance. This interview took place at the 20th International Myeloma Society (IMS) Annual Meeting, held in Athens, Greece.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
